TABLE 3.

Summary of Head and Neck Cancer Patient Experience

Patient ID no.	Cancer site	Initial cTNM stage	Radiation	Chemotherapy	KD (days)
1	Larynx	T4aN2c	70 Gy/35 fx	Cisplatin 100 mg/m2	38a
2	Oropharynx	T3N2	70 Gy/35 fx	Carbo/Taxol weekly	37a
3	Oropharynx	T4bN2b	70 Gy/35 fx	Carbo/Taxol weekly	6
4	Oropharynx	T2N2c	70 Gy/35 fx	Cisplatin 20mg/m2 and Taxol weekly	8
5	Larynx	T3N1	70 Gy/35 fx	Cisplatin 100 mg/m2	2
6	Oropharynx	T4aN2c	70 Gy/35 fx	Cisplatin 40 mg/m2	3
7	Oropharynx	T1N1	70 Gy/35 fx	Cisplatin 100 mg/m2	7
8	Oropharynx	T3N2c	70 Gy/35 fx	Cisplatin 100 mg/m2	37a
9	Oropharynx	T2N2b	70 Gy/35 fx	Cisplatin 100 mg/m2	38a
10	Oral cavity	T4aN2b	66 Gy/33 fx	Cisplatin 100 mg/m2	4
11	Hypopharynx	T3N2c	70 Gy/35 fx	Cisplatin 100 mg/m2	5
12	Hypopharynx	T4aN2c	66 Gy/33 fx	Cisplatin 100 mg/m2	7
Ketosis duration (days)	DLT	Reason for discontinuation	Tumor response	PFS (months)	Overall survival (months)b	Current status
19		Completed	PD (local and distant)	6.28	13.94	Deceased
25		Completed	CR/NED	32.69	48.39	Alive
N/A		Fatigue grade 3	CR/NED	22.7	44.22	Alive
N/A	Hyperuricemia grade 4	DLT	CR/NED	25.99	43.36	Alive
N/A		Diet intolerance	CR/NED	18.66	34.42	Alive
N/A		Nausea grade 2, vomiting grade 1, dehydration grade 2	CR/NED	17.51	33.5	Alive
N/A	Acute pancreatitis grade 3	DLT	PD	5.49	33.21	Alive
24		Completed	CR/NED	16.1	32.81	Alive
25		Completed	CR/NED	12.19	30.51	Alive
N/A		Nausea grade 2, vomiting grade 1	CR/NED	12.62	29.98	Alive
N/A		Nausea grade 2, vomiting grade 1, bloating grade 2	CR/NED	12.55	21.21	Alive
N/A	Hyperuricemia grade 4	DLT	CR/NED	12.39	27.91	Alive

^aCompleted prescribed KD.

^bOverall survival from date of initiation of primary treatment with radiation.

Abbrevations: KD=ketogenic diet; fx=fractions; DLT=dose limiting toxicity; CR=complete response; NED=no evidence of disease; PD= progressed disease; PFS = progression-free survival.